Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
FOLD is in the medium-term down -30% in 1 year.
Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-40.12%||ROE||-74.29%||ROI||-61.43%|
|Current Ratio||7.19||Quick Ratio||Long Term Debt/Equity||0.07||Debt Ratio||0.2|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||4.06 M||Cash From Investing Activities||21.66 M||Cash From Operating Activities||-20.98 M||Gross Profit|
|Net Profit||-24.29 M||Operating Profit||-24.06 M||Total Assets||192.62 M||Total Current Assets||151.25 M|
|Total Current Liabilities||21.02 M||Total Debt||14.4 M||Total Liabilities||88.61 M||Total Revenue|
|High 52 week||17.09||Low 52 week||8.38||Last close||11.44||Last change||-5.22%|
|RSI||43||Average true range||0.58||Beta||1.17||Volume||3.52 M|
|Simple moving average 20 days||-2.41%||Simple moving average 50 days||6.18%||Simple moving average 200 days||-12.66%|
|Performance Week||0.88%||Performance Month||5.05%||Performance Quart||-3.87%||Performance Half||-19.38%|
|Performance Year||-30.24%||Performance Year-to-date||19.42%||Volatility daily||3%||Volatility weekly||6.7%|
|Volatility monthly||13.73%||Volatility yearly||47.55%||Relative Volume||222.44%||Average Volume||2.78 M|
|New High||New Low|
2019-03-20 07:00:00 | Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
2019-03-07 14:52:00 | Amicus Therapeutics Looks Impressive If it Can Rally Above $18
2019-03-06 14:39:58 | Will Amicus Therapeutics, Inc.’s NASDAQ:FOLD Earnings Grow In The Years Ahead?
2019-03-01 11:59:04 | Amicus FOLD Reports Wider-than-Expected-Loss for 2018
2019-02-28 14:39:52 | Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT
2019-02-28 12:04:47 | Amicus Therapeutics Inc FOLD Q4 2018 Earnings Conference Call Transcript
2019-02-28 06:30:00 | Amicus Therapeutics, Inc. to Host Earnings Call
2019-02-26 07:32:04 | N.J. biotech firm expanding to Philadelphia, creating 200 new jobs
2019-02-26 07:00:00 | Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
2019-02-25 09:02:02 | What's in Store for Universal Health UHS Q4 Earnings?
2019-02-22 16:36:09 | What's in Store for Teladoc's TDOC Q4 Earnings?
2019-02-21 10:31:03 | Amicus Therapeutics FOLD Expected to Beat Earnings Estimates: Should You Buy?
2019-02-20 09:32:02 | Tenet Healthcare THC Q4 Earnings: What's in the Offing?
2019-02-13 07:30:00 | New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019
2019-02-12 07:00:00 | Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019
2019-02-11 16:51:09 | Zoetis ZTS to Report Q4 Earnings: What's in the Cards?
2019-02-04 10:38:00 | 2 Small-Cap Stocks That Are Still a Bargain
2019-01-24 10:08:03 | Amicus FOLD Boasts Strong Pipeline Amid Stiff Competition
2019-01-16 08:05:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics
2019-01-15 09:00:00 | Is Amicus Therapeutics' Sharp Reversal Warranted?
2019-01-10 07:30:00 | Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2019-01-07 07:00:00 | Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance
2019-01-03 16:01:00 | Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
2019-01-03 07:00:00 | Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
2019-01-02 16:00:02 | How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
2018-12-28 11:10:02 | A Financial Overview of Vanda Pharmaceuticals in December
2018-12-28 09:35:48 | Vanda Pharmaceuticals: Recent Developments and Analyst Ratings
2018-12-19 16:01:00 | Amicus Therapeutics Announces Executive Team Updates
2018-12-12 10:58:41 | Should You Worry About Amicus Therapeutics, Inc.’s NASDAQ:FOLD CEO Pay?
2018-12-11 16:01:00 | Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® Migalastat
2018-12-11 07:05:00 | Today's Research Reports on Trending Tickers: EQT Corporation and Transocean Ltd.
2018-12-10 03:21:53 | Amicus Therapeutics, Inc. FOLD Hedge Funds Are Snapping Up
2018-12-04 07:35:00 | Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis, Key Performance Indications
2018-11-14 06:55:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen
2018-11-13 08:07:33 | Jazz Pharmaceuticals: Analysts’ View in November
2018-11-12 07:00:00 | Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
2018-11-05 13:25:37 | Edited Transcript of FOLD earnings conference call or presentation 5-Nov-18 1:30pm GMT
2018-11-05 08:45:01 | Amicus Therapeutics FOLD Reports Q3 Loss, Lags Revenue Estimates
2018-11-05 07:42:22 | Amicus Therapeutics: 3Q Earnings Snapshot
2018-11-05 07:00:00 | Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
2018-10-29 08:00:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron
2018-10-29 07:00:00 | Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018
2018-10-25 09:25:00 | Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences — Renewed Outlook, Key Drivers of Growth
2018-10-22 13:56:07 | 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout